In an aggressive TNBC mouse model, treatment with PARPi + SREBP1 inhibitor + CSF-1 inhibitor significantly improved tumor growth inhibition compared to CSF-1 inhibitor + olaparib (Mehta et al., 2021). This evidence concerns the gene SREBF1 and neoplasm.